Renal & Urology News
Caroline Helwick
February 05, 2010
NEW ORLEANS—Acute renal failure (ARF) induced by pathogenic light chains can be the first presenting sign of multiple myeloma, and prompt treatment of the malignancy is critical to reversing renal damage, according to a study presented by European investigators at the American Society of Hematology 51st annual meeting.
“This is an oncologic emergency and you need very active myeloma treatment to correct...
Seattle Genetics and Millennium Announce Initiation of Phase I Combination Clinical Trial of Brentuximab Vedotin (SGN-35) for Front-line Hodgkin Lymphoma
Businesss Wire
February 03, 2010 09:00 AM Eastern Time
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy...
Sopherion Therapeutics Receives FDA Fast Track Designation for Myocet in Metastatic Breast Cancer
PRINCETON, N.J., Jan. 7 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced today that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for nonpegylated liposomal doxorubicin (Myocet(TM)) for first-line therapy of HER2 positive metastatic breast cancer....
CytRx Announces Plan To Initiate A Phase 2 Clinical Trial With INNO-206 In Patients With Advanced Soft Tissue Sarcomas
Medical News Today
Article Date: 25 Nov 2009 - 15:00 PST
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company, today announced plans to initiate a multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a treatment for patients with advanced soft tissue sarcomas who have failed surgery and radiation. Soft tissue sarcomas...
Medical News Today
Article Date: 23 Oct 2009 - 3:00 PDT
Cancer patients don't have time to waste, yet many must endure a tedious process of elimination as physicians try several different treatments until identifying the one that is most effective against their particular type of tumor. Now researchers at the University of Virginia Health System have developed a breakthrough method that could one day eliminate this trial and error approach to treating many cancers.
